Quick Answer
InMed Pharmaceuticals Inc. reported Total Assets of $15.58 million for the year ending 2025.
- InMed Pharmaceuticals Inc. showed an increase of +31.8% in Total Assets from 2024 to 2025.
- This data is from InMed Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $6.60 million | Q4 2020: $11.75 million | Q1 2021: $12.34 million | Q3 2021: $17.33 million | Q4 2021: $19.38 million | Q1 2022: $15.49 million | Q3 2022: $14.58 million | Q4 2022: $16.92 million | Q1 2023: $14.73 million | Q3 2023: $10.92 million | Q4 2023: $15.26 million | Q1 2024: $13.36 million | Q3 2024: $10.47 million | Q4 2024: $8.50 million | Q1 2025: $9.28 million | Q2 2025: $15.58 million | Q3 2025: $13.36 million | Q4 2025: $11.19 million.
- Over the full 6 years of available data (2020 to 2025), InMed Pharmaceuticals Inc.'s Total Assets has grown by 99.7%.
- Historical annual values: Fiscal year 2025: $15.58 million | Fiscal year 2024: $11.82 million | Fiscal year 2023: $14.11 million | Fiscal year 2022: $12.79 million | Fiscal year 2021: $9.78 million | Fiscal year 2020: $7.80 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: